Figure 2.
Potential delivery strategies for lncRNA H19 is proposed in OA treatment. (A) Nanotechnology and lncRNA-loaded exosomes could overcome the low efficiency of in vivo transgene lncRNA transfection, which would be applicable for widespread clinical application of gene therapy targeting lncRNAs. (B) Various transgene technologies may benefit lncRNA overexpression or downregulations in vivo studies, which opened a new door in studying the delivery of genetic material for OA treatment.